Nitric oxide regulates cytokine induction in the diaphragm in response to inspiratory resistive breathing

J Appl Physiol (1985). 2012 Nov;113(10):1594-603. doi: 10.1152/japplphysiol.00233.2012. Epub 2012 Sep 6.

Abstract

Resistive breathing (encountered in chronic obstructive pulmonary disease and asthma) results in cytokine upregulation and decreased nitric oxide (NO) levels in the strenuously contracting diaphragm. NO can regulate gene expression. We hypothesized that endogenously produced NO downregulates cytokine production triggered by strenuous diaphragmatic contraction. Wistar rats treated with vehicle, the nonselective NO synthase inhibitor NG-nitro-l-arginine-methylester (l-NAME), or the NO donor diethylenetriamine-NONOate (DETA) were subjected to inspiratory resistive breathing (IRB; 50% of maximal inspiratory pressure) for 6 h or sham operation. Additional groups of rats were subjected to IRB for 6 h with concurrent administration of l-NAME and inhibitors of NF-κB (BAY-11-7082), ERK1/2 (PD98059), or P38 (SB203580). Inhibition of NO production (with l-NAME) resulted in upregulation of IRB-induced diaphragmatic IL-6, IL-10, IL-2, TNF-α, and IL-1β levels by 50%, 53%, 60%, 47%, and 45%, respectively. In contrast, the NO donor (DETA) attenuated the IRB-induced cytokine upregulation to levels characteristic of quietly breathing animals. l-NAME augmented IRB-induced activation of MAPKs (P38 and ERK1/2) and NF-κB, whereas DETA triggered the opposite effect. NF-κB and ERK1/2 inhibition in l-NAME-treated animals blunted the l-NAME-induced cytokine upregulation except IL-6, whereas P38 inhibition blunted all (including IL-6) cytokine upregulation. NO downregulates IRB-induced cytokine production in the strenuously contracting diaphragm through its action on MAPKs and NF-κB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cytokines / metabolism*
  • Diaphragm / drug effects
  • Diaphragm / immunology
  • Diaphragm / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Inflammation / immunology
  • Inflammation / metabolism*
  • Inflammation / physiopathology
  • Inhalation*
  • Lung Diseases, Obstructive / immunology
  • Lung Diseases, Obstructive / metabolism*
  • Lung Diseases, Obstructive / physiopathology
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism
  • Muscle Contraction*
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / metabolism
  • Oxidation-Reduction
  • Protein Carbonylation
  • Rats
  • Rats, Wistar
  • Signal Transduction
  • Time Factors
  • Work of Breathing

Substances

  • Cytokines
  • Enzyme Inhibitors
  • NF-kappa B
  • Nitric Oxide Donors
  • Nitric Oxide
  • Nitric Oxide Synthase
  • Mitogen-Activated Protein Kinases